Navigation Links
Sir Walter Bodmer Joins Oxford Genome Sciences Scientific Advisory Board
Date:10/11/2007

OXFORD, England, October 11 /PRNewswire/ -- Oxford Genome Sciences (UK) Ltd "OGeS" announces today that it has further strengthened its Scientific Advisory Board (SAB) with the appointment of Sir Walter Bodmer, currently Head of the Cancer and Immunogenetics Laboratory in the Weatherall Institute of Molecular Medicine at the University of Oxford, which is actively researching the fundamental genetic and biological changes which lead to the development of colorectal cancer.

In addition to the SAB appointment, OGeS and Sir Walter's laboratory will collaborate on the evaluation of OGeS cancer drug development candidates in the area of colorectal cancer.

Prior to taking up his current position, Sir Walter Bodmer was the Director General of the Imperial Cancer Research Fund, London, a position he assumed after having been the Fund's Director of Research for 12 years. Before joining the Imperial Cancer Research Fund, he was the Professor of Genetics at the University of Oxford. Dr Bodmer moved to Oxford University from Stanford University where he was a Professor in the Department of Genetics.

Dr Bodmer, who has developed models for population genetics, worked extensively on the HLA system and the use of somatic cell hybrids for human linkage studies, received his Ph.D. in Genetics in 1959 from the University of Cambridge. He became a fellow of the Royal Society in 1974, a foreign member of the US national Academy of Sciences in 1981 and was knighted in 1986 for his contributions to science.

Dr Christian Rohlff, CEO of OGeS commenting on today's announcement said:

"I am delighted that someone of Walter's scientific standing has agreed to join our Scientific Advisory Board. I am sure his broad ranging experience in genetics and biology and his current work in the field of colorectal cancer will allow him to make an important contribution to OGeS as we continue to further develop our position in the exciting field of personalised medicines. With our collaborations with both Medarex and Biosite making significant progress, these are exciting times for OGeS."

Sir Walter Bodmer commenting on his appointment said:

"I have been highly impressed with the team of people that Christian has built at Oxford Genome Sciences. I am looking forward to working with them and bringing my expertise to help the company developing the personalised medicines that I believe are needed to dramatically improve the treatment of cancer."

About Oxford Genome Sciences

Oxford Genome Sciences (OGeS) is focused on the development of targeted medicines for oncology. The company uses OGAP(R), which it has developed into the world's largest cancer protein database, to discover novel clinically relevant drug targets and diagnostics.

OGeS' strategy is to use its unique and integrated OGAP(R) discovery platform in alliances with the world's leading antibody companies to develop OGeS targets into new antibody therapeutics and diagnostics that will deliver innovative and cost-effective medicines to fulfil unmet patient needs in the field of cancer. The company has signed a number of collaborations in the area of cancer, which are together designed to achieve OGeS' objective of developing novel personalised solutions to the management of cancer. Specifically in 2006, OGeS entered into partnerships with Medarex to discover, develop and commercialise new human antibody therapeutics for the treatment of cancers and with Biosite to develop a new diagnostic protein panel for relapsing colorectal cancer. In parallel, OGeS provides biomarker discovery and screening services to pharmaceutical and biotechnology companies.

OGeS, a privately held company, was formed in 2004 and is based near Oxford, UK.

About OGAP(R)

Oxford Genome Anatomy Project (OGAP) holds the world's largest proprietary collection of proteins represented by the database, which contains over one million peptide sequences from 50 tissues and 60 disease states, mapped to approximately 15,000 genes and over eight million SNPs and haplotypes. The database can be customised for individual partners to support and enhance their preclinical and clinical drug development activities.

OGAP(R) is a registered trade mark of Oxford Genome Sciences (UK) Ltd.

For further information, please see http://www.oxfordgenomesciences.com

For further information, please contact:

Oxford Genome Sciences

Dr Christian Rohlff, Chief Executive Officer

Tel: +44-(0)1235-861-770

christian.rohlff@oxfordgenomesciences.com

Citigate Dewe Rogerson

David Dible, Valerie Auffray

Tel: +44-(0)207-638-9571

valerie.auffray@citigatedr.co.uk


'/>"/>
SOURCE Oxford Genome Sciences
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Chemical-petroleum executive joins Virent Energy board
2. Schneider National exec joins TrafficCast board
3. Doyle joins governors in support of stem cell bill
4. Genomics researcher Hood joins NimbleGen board
5. Fergus joins Baird Venture Partners, Caden Bio
6. Meier joins Broadlook Technologies as COO
7. Prodesse joins forces with Invitrogen
8. Wisconsin joins price-fixing suit vs. D-RAM makers
9. Napier joins board of Third Wave Technologies
10. Schmidt rejoins Renaissance Learning
11. Tommy Thompson joins drug company as advisor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... 5, 2016 According to ... by Products (Consumable, Instruments, Automated Cell Expansion System), ... Stem Cell Research, Cancer, and Cell-Based Research), End-users ... - Global Revenue, Trends, Growth, Share, Size and ... the global cell expansion market is expected to ...
(Date:12/5/2016)... /PRNewswire/ - Resverlogix Corp. ("Resverlogix" or the "Company") ... Safety Monitoring Board (DSMB) for the Company,s Phase ... patients has completed a second planned safety review ... planned without any modifications. The DSMB reviewed available ... efficacy concerns were identified. The DSMB will conduct ...
(Date:12/5/2016)... , Dec. 5, 2016  Eisai Inc. ... open-label two-year study of rufinamide, which were presented ... Epilepsy Society (AES) held from December 2-6 in ... final two-year safety, tolerability and cognitive data showed ... experienced similar safety and tolerability profiles, cognitive development ...
(Date:12/5/2016)... 2016 The U.S. Biotechnology industry ... billion of revenue and some $890 billion of total ... global biopharmaceuticals, and this figure is expected to exceed ... up these four equities for assessment: Northwest Biotherapeutics Inc. ... ACAD ), Acorda Therapeutics Inc. (NASDAQ: ...
Breaking Biology Technology:
(Date:6/20/2016)... Securus Technologies, a leading provider of ... safety, investigation, corrections and monitoring announced that after ... secured the final acceptance by all three (3) ... Systems (MAS) installed. Furthermore, Securus will have contracts ... by October, 2016. MAS distinguishes between legitimate wireless ...
(Date:6/9/2016)... Paris Police Prefecture ... solution to ensure the safety of people and operations in ... major tournament Teleste, an international technology group specialised ... today that its video security solution will be utilised by ... public safety across the country. The system roll-out is scheduled ...
(Date:6/2/2016)... --  The Weather Company , an IBM Business (NYSE: ... in which consumers will be able to interact with IBM ... voice or text and receive relevant information about the product ... have long sought an advertising solution that can create a ... and valuable; and can scale across millions of interactions and ...
Breaking Biology News(10 mins):